What does the safety data show for Semaglutide?

Semaglutide, and other drugs in the same category (glucagon-like peptide GLP-1 receptor antagonists), have been available in the market for over a decade. This is according to Andersen-Lange, Novo Nordisk’s products.

Additionally, the safety data gathered from clinical trials and post marketing surveillance have not shown any conclusive evidence linking them to thyroid cancer.